Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medennium Inc.

This article was originally published in Start Up

Executive Summary

Phakic intraocular lenses may offer solutions for patients that suffer from high degrees of myopia or hyperopia, Medennium Inc. 's PRL, in phase II clinical trials, is a posterior phakic intraocular lens.

You may also be interested in...



Refractive Surgery

For the ultimate in convenience, hundreds of thousands of nearsighted and farsighted patients are turning to refractive surgery, or surgical vision correction procedures that promise a permanent alternative to glasses. New companies that wish to grab a portion of the $12 billion US market for vision correction are avoiding the crowded and competitive excimer laser business, with technologies that treat patients that LASIK (laser in-situ keratomileusis) doesn't serve well.

UK Grants First Worldwide Authorization For PfIzer/BioNTech COVID-19 Vaccine

The UK has approved the mRNA-based vaccine just nine days after receiving the final Phase III results from Pfizer.

Wockhardt Preps To Deliver 100M Doses Of AZ Vaccine

As the MHRA prepares to grant approval to the Oxford/AstraZeneca vaccine, Wockhardt is set to supply 100 million doses for the UK government’s own use and its WHO commitments. The company is also in talks with global vaccine developers to manufacture their COVID-19 vaccines for emerging economies

Topics

Related Companies

UsernamePublicRestriction

Register

OM004514

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel